Daiichi Sankyo (OTCMKTS:DSNKY) Sees Large Volume Increase – Time to Buy?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) saw unusually-strong trading volume on Friday . Approximately 1,915,564 shares changed hands during trading, an increase of 196% from the previous session’s volume of 647,620 shares.The stock last traded at $18.45 and had previously closed at $18.15.

Analyst Ratings Changes

Separately, Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy”.

Daiichi Sankyo Stock Performance

The company has a 50-day moving average price of $21.22 and a two-hundred day moving average price of $23.33. The company has a quick ratio of 1.60, a current ratio of 2.69 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $34.40 billion and a P/E ratio of 15.93.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings results on Thursday, January 29th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.25 by $0.05. The firm had revenue of $3.65 billion during the quarter, compared to the consensus estimate of $3.88 billion. Daiichi Sankyo had a net margin of 15.40% and a return on equity of 18.39%. Equities analysts expect that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.73 earnings per share for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.